nach oben

The European Journal of Health Economics

Erschienen in:

01.11.2004 | Pricing and reimbursement

Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden

The first year

verfasst von: Joakim Ramsberg, Stefan Odeberg, Andreas Engström, Douglas Lundin

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Abstract

This study assessed the quality of health economic documentation submitted to the Pharmaceutical Benefits Board (PBB) in Sweden. Two different instruments were used in the evaluation: the PBB checklist, which was constructed by the authors from the PBB guidelines for health economic evaluations, and the QHES, a validated quality assessment instrument. Some areas that seem especially problematic, or where the quality was particularly low are identified and discussed. Also, we present the cost per quality-adjusted life-year that the companies have presented and how this related to the PBBs decisions.

Nur mit Berechtigung zugänglich

Bradley CA, Iskedjian M, Lancot KL et al. (1995) Quality assessment of economic evaluations in selected pharmacy, medical and health economics journals. Ann Pharmacother 29:681–689PubMed

Kumar, Ritesh N, Raisch, Dennis W, Borrego, Matthew E (2002) Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia. Expert Rev Pharmacoecon Outcomes Res 2:565–575

Iskedjian M, Trakas K, Bradley CA et al. (1997) Quality assessment of economic evaluations published in pharmacoeconomics. Pharmacoeconomics 12:685–694PubMed

Baladi J-F, Menon D, Otten N (1998) Use of economic evaluation guidelines: 2 years’ experience in Canada. Health Econ 7:221–227CrossRefPubMed

Anis AH, Gagnon Y (2000) Using economic evaluations to make formulary coverage decisions: so much for guidelines. Pharmacoeconomics 18:55–62PubMed

Hill SR, Mitchell AS, Henry DA (2000) Problems with the interpretation of pharmaeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2116–21

Pharmaceutical Benefits Board (2003) General guidelines for economic evaluations from the Pharmaceuticals Benefits Board. LFNAR 2003, 2. Available athttp://www.lfn.se/documents/In%20English/ENG_lfnar2003-eng.pdf. Accessed November 18

Ofman, Joshua J, Sullivan, Sean D, Neumann, Peter J, Chiou, Chiun-Fang, Henning, James M, Wade, Sally W, Hay JW (2003) Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Managed Care Pharm 9:53–61

Philips Z, Ginelly L, Sculpher M, Claxton K (2003) A review of guidelines for good practice in decision-analytic modelling in health technology assessment. Presented at the Society for Medical Decision Making, 25th annual meeting. October , Chicago

Titel: Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden
The first year
verfasst von: Joakim Ramsberg
Stefan Odeberg
Andreas Engström
Douglas Lundin
Publikationsdatum: 01.11.2004
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 4/2004
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-004-0246-1

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2004

Using diagnosis-related groups

Direct medical costs of monitoring and treating patients with Takayasu arteritis in Italy

Drug price regulation under consumer moral hazard

What reimbursement for coronary revascularization with drug-eluting stents?

A note on the impact of hours worked on mortality in OECD countries

Willingness to pay for dental fear treatment